Loading...

Knight Therapeutics Inc.

GUD.TOTSX
Healthcare
Drug Manufacturers - Specialty & Generic
CA$6.45
CA$0.08(1.26%)

Knight Therapeutics Inc. (GUD.TO) Stock Competitors & Peer Comparison

See (GUD.TO) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GUD.TOCA$6.45+1.26%642.8M64.50CA$0.10N/A
CURA.CNCA$5.22+9.21%4.1B-6.07-CA$0.86N/A
BHC.TOCA$10.38-0.48%3.8B28.83CA$0.36N/A
CURA.TOCA$3.90-1.27%3B-7.96-CA$0.49N/A
GTII.CNCA$11.57-2.61%2.7B77.13CA$0.15N/A
VRNO.CNCA$6.32+6.76%2.2B-5.40-CA$1.17N/A
TRUL.CNCA$11.03+0.27%1.9B-9.85-CA$1.12N/A
TLRY.TOCA$1.59+2.58%1.7B-0.47-CA$3.40N/A
CRON.TOCA$3.61+1.69%1.4B51.57CA$0.07N/A
TER.CNCA$2.38-0.42%804.8M-1.33-CA$1.79N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GUD.TO vs CURA.CN Comparison August 2025

GUD.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUD.TO stands at 642.8M. In comparison, CURA.CN has a market cap of 4.1B. Regarding current trading prices, GUD.TO is priced at CA$6.45, while CURA.CN trades at CA$5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUD.TO currently has a P/E ratio of 64.50, whereas CURA.CN's P/E ratio is -6.07. In terms of profitability, GUD.TO's ROE is +0.00%, compared to CURA.CN's ROE of -0.25%. Regarding short-term risk, GUD.TO is less volatile compared to CURA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for GUD.TO.Check CURA.CN's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;